Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology. (1st January 2021)

• Record Type: Journal Article
• Authors: Skrahina, Volha; Grittner, Ulrike; Beetz, Christian; Skripuletz, Thomas; Juenemann, Martin; Krämer, Heidrun H.; Hahn, Katrin; Rieth, Andreas; Schaechinger, Volker; Patten, Monica; Tanislav, Christian; Achenbach, Stephan; Assmus, Birgit; Knebel, Fabian; Gingele, Stefan; Skrahin, Aliaksandr; Hartkamp, Jörg; Förster, Toni M.; Roesner, Sabine; Pereira, Catarina; Rolfs, Arndt
• Is Part Of: Annals of medicine. Volume 53:Number 1(2021)
• Page Start: 1787
• Page End: 1796
• Publication Date: 2021-01-01
• Subjects: Hereditary transthyretin-related amyloidosis -- polyneuropathy -- cardiomyopathy -- genetic testing; Medicine -- Periodicals; 610
• DOI: 10.1080/07853890.2021.1988696
• Languages: English
• ISSNs: 0785-3890

Abstract

Abstract: Background: Hereditary Transthyretin-Related Amyloidosis, a clinically heterogeneous autosomal dominant disease caused by pathogenic variants in the TTR gene, is characterized by the deposition of insoluble misfolded protein fibrils. The diagnosis, especially in non-endemic areas, is typically delayed by 4–5 years; a misdiagnosis due to clinical heterogeneity is common. The study objective was to define the prevalence of Hereditary Transthyretin-Related Amyloidosis in patients with polyneuropathy and/or cardiomyopathy of no obvious aetiology. Method: A multicenter observational "Epidemiological analysis for the hereditary Transthyretin-Related AMyloidosis"—TRAM study was performed in Germany, Austria, and Switzerland. Results: A total of 5141 participants were recruited by 50 neurologic and 27 cardiologic specialized centres. Genetic analysis demonstrated a 1.1% Hereditary Transthyretin-Related Amyloidosis positivity rate among patients with polyneuropathy and/or cardiomyopathy of not obvious aetiology. Twenty-one various TTR variants ( TTR -positive) were identified. Body Mass Index was lower in the TTR -positive patients as an indicator for the involvement of the autonomic nervous system; the age of onset of clinical manifestations was higher in TTR -positive patients. There were no other genotype-phenotype correlations or the prevalence of specific clinical manifestations in TTR -positive patients. Conclusions: Our data support the fact that Hereditary Transthyretin-Related Amyloidosis is underdiagnosed in polyneuropathy and cardiomyopathy patients. Routine implementation of genetic testing is recommended in patients with unexplained polyneuropathy and/or cardiomyopathy to accelerate the earlier diagnosis and the time-sensitive treatment initiation. KEY MESSAGES: More than 5.000 participants with CM and/or PNP of no obvious aetiology were recruited in the observational "Epidemiological analysis for the hereditary Transthyretin-Related AMyloidosis" TRAM study and screened for pathogenic TTR variants. The study demonstrated >1% of patients with CM and/or PNP of unclear aetiology are positive for a pathogenic TTR variant. Routine genetic testing is recommended in patients with unexplained CM and/or PNP to accelerate the initial diagnosis and timely treatment initiation.